Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid.
Although a crystal structure and a pharmacophore model are available for cytochrome P450 2C8, the role of protein flexibility and specific ligand-protein interactions that govern substrate binding are poorly understood. X-ray crystal structures of P450 2C8 complexed with montelukast (2.8 A), troglitazone (2.7 A), felodipine (2.3 A), and 9-cis-retinoic acid (2.6 A) were determined to examine ligand-protein interactions for these chemically diverse compounds. Montelukast is a relatively large anionic inhibitor that exhibits a tripartite structure and complements the size and shape of the active-site cavity. The inhibitor troglitazone occupies the upper portion of the active-site cavity, leaving a substantial part of the cavity unoccupied. The smaller neutral felodipine molecule is sequestered with its dichlorophenyl group positioned close to the heme iron, and water molecules fill the distal portion of the cavity. The structure of the 9-cis-retinoic acid complex reveals that two substrate molecules bind simultaneously in the active site of P450 2C8. A second molecule of 9-cis-retinoic acid is located above the proximal molecule and can restrain the position of the latter for more efficient oxygenation. Solution binding studies do not discriminate between cooperative and noncooperative models for multiple substrate binding. The complexes with structurally distinct ligands further demonstrate the conformational adaptability of active site-constituting residues, especially Arg-241, that can reorient in the active-site cavity to stabilize a negatively charged functional group and define two spatially distinct binding sites for anionic moieties of substrates.
Schoch
Guillaume A
GA
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA.
Yano
Jason K
JK
Sansen
Stefaan
S
Dansette
Patrick M
PM
Stout
C David
CD
Johnson
Eric F
EF
D000085:Acetates / Q000494:pharmacology; D000077556:Alitretinoin; D001189:Aryl Hydrocarbon Hydroxylases / Q000737:chemistry*; D001665:Binding Sites; D002839:Chromans / Q000494:pharmacology*; D018360:Crystallography, X-Ray / Q000379:methods; D003521:Cyclopropanes; D065727:Cytochrome P-450 CYP2C8; D015736:Felodipine / Q000494:pharmacology*; D006418:Heme / Q000737:chemistry; D006801:Humans; D007501:Iron / Q000737:chemistry; D020024:Leukotriene Antagonists / Q000494:pharmacology; D008024:Ligands; D008968:Molecular Conformation; D011485:Protein Binding; D011804:Quinolines / Q000494:pharmacology; D013379:Substrate Specificity; D013440:Sulfides; D045162:Thiazolidinediones / Q000494:pharmacology*; D014212:Tretinoin / Q000494:pharmacology*; D000077288:Troglitazone
D000085:Acetates; D002839:Chromans; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D008024:Ligands; D011804:Quinolines; D013440:Sulfides; D045162:Thiazolidinediones; D000077556:Alitretinoin; D006418:Heme; D014212:Tretinoin; D007501:Iron; D001189:Aryl Hydrocarbon Hydroxylases; C450259:CYP2C8 protein, human; D065727:Cytochrome P-450 CYP2C8; D000077288:Troglitazone; C093875:montelukast; D015736:Felodipine